ATE452642T1 - Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen - Google Patents

Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen

Info

Publication number
ATE452642T1
ATE452642T1 AT05024864T AT05024864T ATE452642T1 AT E452642 T1 ATE452642 T1 AT E452642T1 AT 05024864 T AT05024864 T AT 05024864T AT 05024864 T AT05024864 T AT 05024864T AT E452642 T1 ATE452642 T1 AT E452642T1
Authority
AT
Austria
Prior art keywords
cox
inhibitors
affective disorders
treat affective
treat
Prior art date
Application number
AT05024864T
Other languages
English (en)
Inventor
Norbert Mueller
Original Assignee
Norbert Mueller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10129320A external-priority patent/DE10129320A1/de
Application filed by Norbert Mueller filed Critical Norbert Mueller
Application granted granted Critical
Publication of ATE452642T1 publication Critical patent/ATE452642T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05024864T 2001-06-19 2002-05-31 Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen ATE452642T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10129320A DE10129320A1 (de) 2001-06-19 2001-06-19 Verwendung von COX-2 Inhibitoren zur Behandlung von Schizophrenie, wahnhaften Störungen, affektiven Störungen oder Ticstörungen
US36490402P 2002-03-14 2002-03-14

Publications (1)

Publication Number Publication Date
ATE452642T1 true ATE452642T1 (de) 2010-01-15

Family

ID=26009543

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05024864T ATE452642T1 (de) 2001-06-19 2002-05-31 Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
AT02738138T ATE338557T1 (de) 2001-06-19 2002-05-31 Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02738138T ATE338557T1 (de) 2001-06-19 2002-05-31 Verwendung von cox2 inhibitoren zur behandlung von schizophrenia und des ticks

Country Status (16)

Country Link
US (1) US20040204469A1 (de)
EP (2) EP1627639B1 (de)
JP (2) JP4205577B2 (de)
AP (1) AP1512A (de)
AT (2) ATE452642T1 (de)
AU (1) AU2002312967A1 (de)
CA (1) CA2448025C (de)
CY (1) CY1109949T1 (de)
DE (2) DE60214542T2 (de)
DK (2) DK1397145T3 (de)
EA (1) EA009780B1 (de)
ES (2) ES2271269T3 (de)
OA (1) OA12627A (de)
PT (2) PT1397145E (de)
SI (1) SI1627639T1 (de)
WO (1) WO2002102297A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR032641A1 (es) * 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US8703772B2 (en) 2001-09-25 2014-04-22 Otsuka Pharmaceutical Co., Ltd. Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
DK1567164T3 (da) * 2002-11-26 2009-05-18 Alexza Pharmaceuticals Inc Anvendelse af loxapin til fremstilling af et lægemiddel til behandling af smerte
US20040204411A1 (en) * 2002-12-17 2004-10-14 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
BRPI0410378A (pt) * 2003-05-16 2006-06-13 Pfizer Prod Inc tratamento de distúrbios psicóticos e depressivos
EP1625334B9 (de) 2003-05-21 2012-07-25 Alexza Pharmaceuticals, Inc. Schlag gezündete unabhängige heizeinheit
EP1660065A2 (de) * 2003-08-27 2006-05-31 Eli Lilly And Company Behandlung von pervasiven entwicklungsstörungen mit norepinephrin-wiederaufnahme-hemmern
EP1687000A2 (de) * 2003-11-19 2006-08-09 Glaxo Group Limited Verwendung von cyclooxygenase-2-hemmern zur behandlung von depressionen
EP1687001A2 (de) * 2003-11-19 2006-08-09 Glaxo Group Limited Verwendung von cyclooxygenase-2-selektiven hemmern zur behandlung von schizophrenie
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
CA2556380A1 (en) * 2004-03-02 2005-09-15 Pharmacia Corporation Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents
US20070281927A1 (en) * 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
GB0618879D0 (en) 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US20080216828A1 (en) 2007-03-09 2008-09-11 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
JP5144104B2 (ja) 2007-04-09 2013-02-13 ユニ・チャーム株式会社 伸縮性複合シート及びそれを用いた使い捨て着用物品
CA2774963A1 (en) * 2009-10-09 2011-04-14 Prothera, Inc. Compositions and methods comprising pediococcus for reducing at least one symptom associated with autism spectrum disease in a person diagnosed with an autism spectrum disease
EP2340818A1 (de) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Kokristalle von Venlafaxin und Celecoxib
EP2340819A1 (de) * 2009-12-23 2011-07-06 Laboratorios Del. Dr. Esteve, S.A. Zusammensetzungen mit Venlafaxin und Celecoxib zur Behandlung von Schmerzen
WO2019113084A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
SG11202005016SA (en) 2017-12-05 2020-06-29 Sunovion Pharmaceuticals Inc Nonracemic mixtures and uses thereof
KR20220018004A (ko) 2019-06-04 2022-02-14 선오비온 파마슈티컬스 인코포레이티드 조절 방출 제형 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579846A (en) * 1984-10-11 1986-04-01 Pfizer Inc. Antiinflammatory compositions and methods
AU1041599A (en) * 1997-11-13 1999-06-07 Jose Luis Castro Pineiro Therapeutic uses of triazolo-pyridazine derivatives
SK286669B6 (sk) * 1999-07-01 2009-03-05 Pharmacia & Upjohn Company Použitie opticky čistého (S,S)-reboxetínu alebo jeho farmaceuticky prijateľnej soli na výrobu lieku na liečenie alebo prevenciu periférnej neuropatie
EP1142889A1 (de) * 2000-04-03 2001-10-10 Pfizer Products Inc. Pyrazolderivate als entzündungs-/schmerzhemmende Mittel
US6306842B1 (en) * 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor

Also Published As

Publication number Publication date
DK1397145T3 (da) 2007-01-02
JP2008297308A (ja) 2008-12-11
DE60234873D1 (de) 2010-02-04
EA009780B1 (ru) 2008-04-28
US20040204469A1 (en) 2004-10-14
DK1627639T3 (da) 2010-04-26
EP1627639A3 (de) 2006-09-27
EA200301291A1 (ru) 2004-06-24
DE60214542D1 (de) 2006-10-19
CA2448025C (en) 2011-07-05
ES2271269T3 (es) 2007-04-16
ATE338557T1 (de) 2006-09-15
JP4824727B2 (ja) 2011-11-30
EP1397145A2 (de) 2004-03-17
CA2448025A1 (en) 2002-12-27
PT1397145E (pt) 2006-10-31
ES2336682T3 (es) 2010-04-15
CY1109949T1 (el) 2014-09-10
JP2004534066A (ja) 2004-11-11
EP1627639A2 (de) 2006-02-22
OA12627A (en) 2006-06-13
WO2002102297A3 (en) 2003-05-01
EP1397145B1 (de) 2006-09-06
EP1627639B1 (de) 2009-12-23
SI1627639T1 (sl) 2010-04-30
DE60214542T2 (de) 2006-12-21
PT1627639E (pt) 2010-03-01
AP1512A (en) 2005-12-15
AU2002312967A1 (en) 2003-01-02
AP2003002934A0 (en) 2003-12-31
WO2002102297A2 (en) 2002-12-27
JP4205577B2 (ja) 2009-01-07

Similar Documents

Publication Publication Date Title
ATE452642T1 (de) Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen
ATE365042T1 (de) Verwendung von morpholinol zur behandlung von sexuellen funktionsstörungen
ATE288748T1 (de) Verwendung von retigabin zur behandlung von neuropathischen schmerzen
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE308364T1 (de) Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen
ATE414556T1 (de) Verwendung von il-18-inhibitoren zur behandlung und/oder prävention von peripheren gefässkrankheiten
DE602004010407D1 (de) Fluorsubstituierter omega-carboxyaryldiphenylharnstoff zur behandlung und prävention von krankheiten und leiden
ATE357440T1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
ATE526982T1 (de) Verwendung von neublastin-polypeptide zur behandlung von neuropathischen schmerzen
ATE395075T1 (de) Verwendung von il-18 inhibitoren zur behandlung und/oder prävention von atherosklerose
ATE353218T1 (de) Verwendung von epinastin zur behandlung von allergischer rhinitis/konjunktivitis
DE60216495D1 (de) Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung
ATE509621T1 (de) Verwendung von 2,5-dihydroxybenzolderivaten zur behandlung von arthritis und schmerzen
DE502004010131D1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE339955T1 (de) Verwendung von escitalopram zur behandlung von generalisierten angstzuständen
ATE380558T1 (de) Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
ATE317261T1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE404203T1 (de) Verwendung von desoxypeganin zur behandlung der klinischen depression
DE60120990D1 (de) Verwendung von 3-bezoylphenylessigsäure-derivaten zur behandlung von netzhauterkrankungen
ATE376416T1 (de) Verwendung von ambroxol zur behandlung von chronischen schmerzen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1627639

Country of ref document: EP